chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Got the shot, then got it three more times/Suspected vaccination failure; got it three more times; So painful; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (The patient got the shot after his/her first bout with shingles).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 24-APR-2022 Reporter's Comment: This case was reported by a patient via interactive digital media. The patient got the shot after his/her first bout with shingles.  Then got it three more times shingles.  The patient stated that anyone could get it inside and it was so painful. The patient further stated that it was life changing and it never seemed to go away. Additional supportive information: This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. Follow up would not possible as no contact details were available.
Patient was administered a vaccine that was withdrawn from a vial outside of the 12 hour window from first puncture. Also reported to manufacturer (spoke with representative), case #MOD22-029369.
Pt fell in the middle of the night, no H/O falls, no dizziness, no nausea
Long term shooting stabbing pain and swelling in right arm, Left hand pain an swelling, tingling, and weakness. Shooting stabbing pain in both legs and cramping in feet. Neck stiffness and pain in upper back. I'm having these symptoms days after my first jab and it's been over a month and I still can't bend my right arm nor grip with left fingers without them cramping painfully.
2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection; 2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection; 2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection; 2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection), VACCINATION SITE SWELLING (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection), VACCINATION SITE PRURITUS (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) and VACCINATION SITE WARMTH (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L10A) for COVID-19 vaccination.     Concurrent medical conditions included Adhesive tape allergy.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection), VACCINATION SITE SWELLING (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection), VACCINATION SITE PRURITUS (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) and VACCINATION SITE WARMTH (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection). At the time of the report, VACCINATION SITE ERYTHEMA (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection), VACCINATION SITE PRURITUS (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) and VACCINATION SITE WARMTH (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) had not resolved and VACCINATION SITE SWELLING (2 inch red, swollen hot and itchy reaction (with a "bull's eye in the middle) on the site of the injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported by investigator o No treatment medications provided by the reporter.    Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: follow up received on 15-Apr-2021 included No new Information
This case was reported by a physician and described the occurrence of injection site cellulitis in a 5-year-old male subject who was vaccinated with combined KINRIX, (GlaxoSmithKline).  The subject's medical history included enlarged tonsil and recurrent streptococcal throat.  On 1 June 2009 the subject received KINRIX (unknown route, left arm) as dose 5 in vaccination series.  On 4 June 2009, 3 days after vaccination with KINRIX, the subject experienced injection site cellulitis and discoloration of skin at injection site.  At the time of reporting the events were unresolved.  The physician considered the events were possibly related to vaccination with KINRIX.  The physician had reported this case to VAERS (reference number unknown).
The patient received a moderna vaccination (unsure if this was her first or second dose) today at the vaccination site at a Stadium.  She went back to her car and became very short of breath, confused, and became minimally responsive.  911 was called.  Upon EMS arrival the patient was agitated and combative.  She received 10 mg of versed.  An OPA was inserted (sating at 98% on OPA) as she was unable to tolerate CPAP. Transported to Hospital.  Given ketamine.  Placed on BIPAP.  ICU admit.  History of CHF, COPD
lots of pain; shivers, chills; the pain was "the normal pain in the arm."; This case was reported by a consumer via call center representative and described the occurrence of pain in a 77-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included herpes virus infection (getting herpes once a year when going out into the sun).   On 10th October 2020, the patient received the 1st dose of Shingrix (intramuscular). On 11th October 2020, 1 days after receiving Shingrix, the patient experienced pain, shivers and pain in arm. Shingrix was interrupted. On 13th October 2020, the outcome of the pain, shivers and pain in arm were recovered/resolved.   It was unknown if the reporter considered the pain, shivers and pain in arm to be related to Shingrix.  Additional details were provided as follows: The patient reported experiencing shivers, chills, and lots of pain after getting the 1st dose of the Shingrix vaccine.  The patient stated that the pain was the normal pain in the arm. The patient reported the vaccine in the left arm at She also stated these occurred the next day and only lasted for about two days.  The health care professional informed her to not get the 2nd dose.  The patient also reported getting herpes once a year when going out into the sun. The reporter consented to follow up.
This case was reported by a healthcare professional via sales representative and described the occurrence of injection site reaction in a 5-year-old male subject who was vaccinated with KINRIX, (GlaxoSmithKline).  Previous and/ or concurrent vaccination included MMR II vaccine (non-gsk); Merck; unknown given on 1 July 2009; VARIVAX (non-gsk); Merck; unknown given on 1 July 2009.  On 1 July 2009 the subject received 1st dose of KINRIX (.5 unknown, unknown, left arm).  On 3 July 2009, 2 days after vaccination with KINRIX, the subject experienced injection site reaction.  At the time of reporting the event was resolved.
pt recvd vax;devel n,fever & pain;tx w/ steroids;
Developed rash all over my body.  Eventually diagnoses as Pityriasis rubra pilaris (PRP) in Jan 2023
Information has been received from a healthcare worker (medical assistant) concerning multiple unspecified patients of unknown age and gender. No concomitant condition, medical history and concomitant therapies were reported. On multiple unspecified dates, unspecified doses of (Oka/Merck) VARIVAX (dosage and route not reported) which were improperly stored under 12.5 F for 20 hours were administered to multiple unspecified patients. The lot # of the (Oka/Merck) VARIVAX included: L039093 with expiration date 06-OCT-2017, L048464 with expiration date 02-DEC-2017, L046884 with expiration date 23-NOV-2017. There was no previous temperature excursion. No adverse effects were reported. This is one of two reports received from the same reporter. Additional information has been requested.
Joint pain in both knees began about 4:00am 4/12/21. Took 2 Tylenol 8hr 650mg every 8 hours for about 48 hours.  Contacted PCP on 4/13/21 and he prescribed Medrol 4 mg pack to also assist with pain relief/inflamation .  Pain subsided after approximately 48 hours from onset. I have continued to take the prescribed Medrol pack as directed by physician.
Initial and follow-up information has been received from a medical assistant concerning a 15 year old female who on 02-APR-2007 was inadvertently vaccinated with a dose of zoster vaccine life (Oka/Merck) (lot # 656607/0163U) instead of varicella virus vaccine live (Oka/Merck) (MSD). It was reported that this was due to human error. It was unspecified if medical attention was sought. There was no product quality complaint involved. No further information was provided. Additional information has been requested.
Swollen and very sore deltoid, fever,  rose to 99.0 (my norm it 96.6), chills, resting heart rate increased dramatically - to 79 from 66 norm.  Felt terrible.  Felt like my body was fighting a bad case of the flu.  Just tinge of a headache. Did not last long.
Pt. reported feeling racing heart rate.  " then I could feel blood pressure increase. But I think I was a bit unsettled by my racing heart. It was like an adrenaline jolt. Fight or flight for no reason. I was feeling pretty normal before that. Just checking my phone waiting for my 15 minutes to pass so I could go home. "No shortness of breath, hives, or rash.  25 mg Benadryl PO administered. 1730 vitals: Sat 100% HR 135 BP 151/104 1733 Vitals: 151/98 Sat 100% HR 120 1735 Vitals: Sat 100% HR 111 1737 Vitals: Sat 100% HR 105 1745 Vitals: HR 106 Sat 99% 1754 vitals: HR 96 Sat 99% 1801:  HR 94 Sat 99% Left 1830 or slightly after. Called ride to take her home. Feeling better when leaving
achy; very sleepy; This case was reported by a consumer and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain, and sleepiness. On an unknown date, the outcome of the pain and sleepiness were recovered/resolved.   It was unknown if the reporter considered the pain and sleepiness to be related to Shingles vaccine.  Additional details were provided as the patient self reported this case. The age at vaccination was not reported. The patient received the shot which made the patient achy and very sleepy. The patient stated that it was worth it. This for tolerance of second dose, refer case US2021AMR179245. Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR179245, 2nd dose.
Information has been received from the registered nurse on 02-JAN-2014. It was reported that GARDASIL vaccines were stored in improper temperatures and were administered to overall number of 132 patients. This report refers to one of the patients involved: a patient of unspecified age and gender, who had been administered dose of GARDASIL (dose and route not reported) on 20-AUG-2013 (lot and expiration date not reported). No adverse event was reported. This is one of the report from the same source. Additional information is not expected.
Covid19 breaktrough.  1st vacciner received on 01/28/2021.  84 y/o with PMHX of stage 4 Non Small cell lung cancer, currently on Immunotherapy-CAPMATINIB, hypothyroidism, HTN  presents to ED via EMS after having syncopal episode at doctor's office.  Pt with 4 day history of poor appetite, fatigue and nausea.  Room air sat 96%, afebrile and CTA chest with stable LUL Cavitary mass with persistent surrounding groundglass infiltrates with mass effect on left major fissure.  Pt started on IV abx and steroids.
The vaccinations were administered around 12:50 pm. She started complaining of itchiness around 1:10pm. 50 mg of diphenhydramine was given at 1:21 pm. Her blood pressure was 118/90 at 1:26 pm and 110/78 at 1:36 pm. Shortly after taking the diphenhydramine she complained of a "funny sensation" in her throat. Paramedics arrived at 1:46 pm and took over her care.
excessive crying 25MAY93 & trembling same day as vax & 10 hrs later;
Pediatric dose given to an adult; Pediatric dose given to an adult; This case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 51-year-old female patient who received HBV (Engerix B pediatric) (batch number YY2R3, expiry date 12th May 2024) for prophylaxis.   On 30th November 2022, the patient received the 2nd dose of Engerix B pediatric. On 30th November 2022, unknown after receiving Engerix B pediatric, the patient experienced adult use of a child product and underdose. On an unknown date, the outcome of the adult use of a child product and underdose were unknown.   Additional Information: GSK Receipt Date: 03-JAN-2023 Reporter's comments: A healthcare professional (HCP) had called to report that a pediatric dose of Engerix-B was given to an adult. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. Additional supportive information: The adult patient had received the Engerix-B pediatric dose, which had led to adult use of a child product and underdose.
Patient is fully vaccinated and boosted twice.  COVID positive on 5/10/2022.72-year-old male who presents complaining of chest pain that is since resolved.  Patient tested positive for COVID earlier today and was getting his infusion at Dr's office.  States that he thinks that his chest pain was brought on by anxiety.  States that he is multiple needles and developed chest pain.  Symptoms resolved.  He was given aspirin in route.  He does have a history of CABG. Positive for chills, fatigue, cough and chest pain. BP 153/85  | Pulse 60  | Temp 98.8 °F (37.1 °C)  | Resp 18  | Ht 198.1 cm (6' 6")  | Wt 99.8 kg (220 lb)  | SpO2 97% EKG: sinus bradycardia, no signs of ischemia and no infarction. Medications: fluid and Nitro.  CXR: acutely unremarkable radiograph of the chest.Left AMA.
Severe weakness, dizziness, headache, ringing in ears and acute memory impairment that is still not resolved
COVID Positive 10/6/21 Hospitalized 10/6/21-10/10/21 Pfizer Dose 1 10/21/21 (EWO217) - note, received vaccine while COVID Positive COVID Positive 10/22/21 COVID Positive 10/23/21  10/19/21: This 52-year-old gentleman presented to the emergency room with complaint of shortness of breath and fever that started a few days ago.  The patient reports shortness of breath, worse with activities. He has a mild cough.  He was recently admitted and treated for COVID pneumonia, and discharged on the October 10, 2021.  On that admission, the patient declined remdesivir treatment.  In the emergency room patient was noted to have some degree of hypoxia and currently is on 6 L of oxygen via nasal cannula.  11/8/21:  Patient has informed me that he wishes to leave against medical advise.  I have discussed all risks associated with this decision including but not limited to respiratory failure renal failure multi organ failure and death.  He endorses understanding he is lucid alert and oriented x3 and responding appropriately.  Again informed him that we are awaiting final recommendations of his transfer team, Nephrology and he will likely need O2 walk as well.  He refuses to stay and wishes to sign out.  Nursing appraised and aware of situation.
fatigue; This is a spontaneous report from a contactable pharmacist. This pharmacist reported for a 41-year-old female patient who received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unknown date as 2nd dose, single dose (at 41-year-old) for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Historical vaccine of the patient included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an 18Dec2020 as 1st dose, single dose (at 41-year-old) for COVID-19 immunization and experienced fatigue and nausea on 18Dec2020. On an unknown date the patient experienced fatigue. The outcome of the event recovered on an unspecified date.   Information on the Lot/Batch Number has been requested. Follow-up attempts were completed. No further information was expected.
PT SAID HE HAS SEVERE MUSCLE ACHES, JOINT PAIN, COUGHING, HAD TROUBLE BREATHING AND WENT BLIND FOR A PERIOD OF TIME.  ALSO NOTED HE HAS COUGHED UP STUFF SINCE THEN.  DID NOT SEEK MEDICAL ATTENTION .
Very itchy. Red blotches all over. Sometimes a whole area gets red. At first and now just sometimes the redness is hot.  I have not had a fever.  Now the blotches just appear randomly.  Sometimes they itch, sometimes they don't. Has been on and off but regular since 11 days after the booster. I had no side effects at all after the 1st 2 Moderna doses and handled them very well. I was also fine immediately after the Moderna booster.  Taking a daily Zyrtec seems to help. At first I did not realize it was related to the booster and tried to rule out histamines. I also have a friend who has similar symptoms and found a whole bunch of comments that sound similar to what I am going through at a website regarding chronic spontaneous urticaria after covid 19 vaccine. Not sure that all those people reported it. Some of the red marks I get look like scratches, yet I haven't scratched myself.  They go away quickly or with a half hour.  There have been some very bad itching days and some not so bad.  Sometimes it gets worse later in the evening closer to when I need to take the Zyrtec. Sometimes not.  It was getting a lot better, but I had a very bad itching day this past weekend.  It has gotten better again. Sometimes if I do scratch, that causes it to itch more, get hot, and/or hurt.  Hot water (shower) used to make it flare up, but lately that has resided.
Rash - broke out with sl. itchy rash on trunk and extremities since yesterday (9/18).
not feeling well and has a really bad exacerbation; coughing; This is a spontaneous report from a contactable consumer or other non hcp (patient) via Pfizer-sponsored program. A female patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection) via an unspecified route of administration on 18Mar2021 (batch or lot number was not reported) as dose 1, single for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On 19Mar2021, at night patient was not feeling well and has a really bad exacerbation and coughing. Therapeutic measures were taken as a result of all the events which included took 3 different medicines. The outcome of the event not feeling well and has a really bad exacerbation was not recovered and outcome of event coughing was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
BODY ACHES; FEVER; HEADACHE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: UNKNOWN expiry: UNKNOWN) .5 ml, administered on 05-MAR-2021 to Right Arm for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 05-MAR-2021, the subject experienced fever. On 05-MAR-2021, the subject experienced headache. On 05-MAR-2021, the subject experienced body aches. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever, headache, and body aches. This report was non-serious.
Blurred Vision. Hx of Fainting when she sees needles84/56 54 18 O2 sat 100% . Refused Transport
her arm is sore and she has a 100.2°F fever; Fever; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of INJECTION SITE PAIN (her arm is sore and she has a 100.2°F fever) and PYREXIA (Fever) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History was provided by the reporter.   On 28-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 29-Jan-2021, the patient experienced INJECTION SITE PAIN (her arm is sore and she has a 100.2°F fever) and PYREXIA (Fever). The patient was treated with ALPRAZOLAM (XANAX) for Sleep difficult, at an unspecified dose and frequency.   At the time of the report, INJECTION SITE PAIN (her arm is sore and she has a 100.2°F fever) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Jan-2021, Body temperature: 100.2 (High) Patient had fever of 100.2 F.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.
Pain, redness, swelling and heat at injection site. Localized to left deltoid, there is a patch approximately 1" X 2" with a hard knot of tissue mass under skin patient stated that there were no other symptoms systemic.  She said symptoms began about 2 hours after vaccination and progressively got worse.
This spontaneous report as received from a other health professional refers to a 12 years old female patient patient with no illness at time of vaccination. The patient was vaccinated with lot # (669796/0840AA) dose 2 GARDASIL, IM on 21-DEC-2011 at 14:34. No other co-suspects were reported. No concomitant medications were reported. It was reported that the patient received immunization that was stored at an improper temp <32 degrees. There were not adverse reactions to vaccine. This is one of several reports from the same source. Additional information is not expected.